• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

促黄体生成素释放激素（LHRH）激动剂和放疗治疗后前列腺腺癌向鳞状细胞癌的转化。

Transformation of a prostatic adenocarcinoma into squamous cell carcinoma after luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy treatment.

机构信息

Université de Tunis El Manar, Faculté de Médecine de Tunis, 1007, Tunis, Tunisie.

The Military Hospital of Tunis, Department of Urology, Montfleury 1008, Tunis, Tunisia.

出版信息

Pan Afr Med J. 2019 Nov 1;34:125. doi: 10.11604/pamj.2019.34.125.19421. eCollection 2019.

DOI:10.11604/pamj.2019.34.125.19421
PMID:33708294
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7906544/
Abstract

Squamous cell carcinoma of the prostate is rare and represents 0.5% to 1% of prostatic carcinomas. Transformation of prostatic adenocarcinoma into squamous cell carcinoma after LH-RH agonist intake has been reported in only 8 cases in the literature. To our knowledge, our case is the second pure squamous cell carcinoma observed after hormonotherapy and radiotherapy. We reported a case of a patient with prostatic adenocarcinoma treated by radical prostatectomy followed by radiotherapy. Eleven years later, he had a vesical recurrence of prostatic adenocarcinoma. Our patient had an endoscopic resection followed by injections of Triptorelin. Six months later, he developed a local recurrence of a squamous cell carcinoma.

摘要

前列腺鳞状细胞癌较为罕见，占前列腺癌的 0.5%至 1%。文献中仅报道了 8 例 LH-RH 激动剂摄入后前列腺腺癌转化为鳞状细胞癌的病例。据我们所知，我们的病例是继激素治疗和放疗后观察到的第二个纯鳞状细胞癌。我们报告了 1 例前列腺腺癌患者，行根治性前列腺切除术，继而行放疗。11 年后，他出现前列腺腺癌的膀胱复发。患者行内镜下切除术，继而行 Triptorelin 注射。6 个月后，他出现局部鳞状细胞癌复发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a0b/7906544/680f12d50647/PAMJ-34-125-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a0b/7906544/401188a3a45b/PAMJ-34-125-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a0b/7906544/17ee1c6ee344/PAMJ-34-125-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a0b/7906544/680f12d50647/PAMJ-34-125-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a0b/7906544/401188a3a45b/PAMJ-34-125-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a0b/7906544/17ee1c6ee344/PAMJ-34-125-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a0b/7906544/680f12d50647/PAMJ-34-125-g003.jpg

相似文献

1
Transformation of a prostatic adenocarcinoma into squamous cell carcinoma after luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy treatment.促黄体生成素释放激素（LHRH）激动剂和放疗治疗后前列腺腺癌向鳞状细胞癌的转化。
Pan Afr Med J. 2019 Nov 1;34:125. doi: 10.11604/pamj.2019.34.125.19421. eCollection 2019.
2
Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer.
J Urol. 1996 Apr;155(4):1357-60.
3
Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-score matching analysis.新辅助LHRH激动剂和雌莫司汀治疗后行根治性前列腺切除术以及新辅助激素治疗后行放疗在高危前列腺癌中均取得了良好的肿瘤学结局：一项倾向评分匹配分析。
World J Surg Oncol. 2014 Apr 30;12:134. doi: 10.1186/1477-7819-12-134.
4
[Complete remission of prostate cancer after LH-RH agonist neoadjuvant therapy: a case report].
Hinyokika Kiyo. 1995 Jun;41(6):485-8.
5
[Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report].[联合内分泌治疗后出现鳞状分化的前列腺癌：一例报告]
Hinyokika Kiyo. 2012 Aug;58(8):457-60.
6
Squamous cell carcinoma at the prostatectomy site: squamous differentiation of recurrent prostate carcinoma.前列腺切除部位的鳞状细胞癌：复发性前列腺癌的鳞状分化
Urology. 1999 Oct;54(4):744. doi: 10.1016/s0090-4295(99)00243-5.
7
[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].[欧洲泌尿外科学会前列腺癌指南。第二部分：晚期、复发性及去势抵抗性前列腺癌的治疗]
Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14.
8
High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.新辅助雄激素剥夺治疗后行根治性前列腺切除术治疗C期前列腺癌的长期随访结果显示失败率较高。
Br J Urol. 1995 Jun;75(6):771-7. doi: 10.1111/j.1464-410x.1995.tb07389.x.
9
Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide.
Urology. 1995 Feb;45(2):329-31. doi: 10.1016/0090-4295(95)80028-x.
10
Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study.促黄体生成素释放激素类似物联合生长抑素类似物与地塞米松对比化疗治疗激素难治性前列腺癌：一项随机II期研究。
Urology. 2004 Jan;63(1):120-5. doi: 10.1016/j.urology.2003.08.041.

引用本文的文献

1
Challenges in the diagnosis of primary squamous cell carcinoma of the prostate: a case report and literature review.前列腺原发性鳞状细胞癌诊断中的挑战：一例报告及文献综述
Front Surg. 2025 Jul 17;12:1532669. doi: 10.3389/fsurg.2025.1532669. eCollection 2025.
2
Unraveling the immune mechanisms and therapeutic targets in lung adenosquamous transformation.揭示肺腺鳞癌转化中的免疫机制和治疗靶点。
Front Immunol. 2025 Jun 3;16:1542526. doi: 10.3389/fimmu.2025.1542526. eCollection 2025.
3
Beyond the norm: exploring the uncommon squamous cell carcinoma of the prostate using a Saudi tumor registry.

本文引用的文献

1
Transformation of adenocarcinoma of prostate to squamous cell carcinoma following hormonal treatment: A case report and review of the literature.激素治疗后前列腺腺癌转化为鳞状细胞癌：一例报告并文献复习
Radiol Case Rep. 2019 Feb 11;14(4):483-489. doi: 10.1016/j.radcr.2019.01.015. eCollection 2019 Apr.
2
Squamous cell carcinoma of the prostate following treatment with an LHRH-agonist: a rare case of transformation of adenocarcinoma of the prostate.促性腺激素释放激素（LHRH）激动剂治疗后发生的前列腺鳞状细胞癌：1例罕见的前列腺腺癌转化病例。
Cent European J Urol. 2014;67(1):26-8. doi: 10.5173/ceju.2014.01.art5. Epub 2014 Apr 17.
3
超越常规：利用沙特肿瘤登记处探索罕见的前列腺鳞状细胞癌
Ann Med Surg (Lond). 2023 Oct 2;85(12):5869-5873. doi: 10.1097/MS9.0000000000001220. eCollection 2023 Dec.
Squamous cell carcinoma of the prostate.
前列腺鳞状细胞癌。
Rev Urol. 2011;13(1):56-60.
4
Diagnostic dilemmas of squamous differentiation in prostate carcinoma case report and review of the literature.前列腺癌中鳞状分化的诊断难题：病例报告及文献复习。
Diagn Pathol. 2011 May 31;6:46. doi: 10.1186/1746-1596-6-46.
5
Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation.前列腺鳞状细胞癌：联合化疗-放疗后的长期生存。
Radiat Oncol. 2007 Apr 3;2:15. doi: 10.1186/1748-717X-2-15.
6
Squamous cell carcinoma of the prostate--a case report.前列腺鳞状细胞癌——病例报告
Int Urol Nephrol. 2005;37(2):311-3. doi: 10.1007/s11255-004-7979-8.
7
Prostate carcinoma with squamous differentiation: an analysis of 33 cases.伴有鳞状分化的前列腺癌：33例分析
Am J Surg Pathol. 2004 May;28(5):651-7. doi: 10.1097/00000478-200405000-00014.
8
Unusual subtypes of prostate cancer.前列腺癌的罕见亚型。
Mod Pathol. 2004 Mar;17(3):316-27. doi: 10.1038/modpathol.3800052.
9
Prostatic adenocarcinoma complicated by the development of epidermoid carcinoma of the urethra; report of two cases.前列腺腺癌合并尿道表皮样癌：2例报告
J Urol. 1956 Feb;75(2):314-23. doi: 10.1016/S0022-5347(17)66814-9.
10
Squamous cell carcinoma of the prostate.前列腺鳞状细胞癌。
Int J Urol. 2003 Feb;10(2):114-6. doi: 10.1046/j.1442-2042.2003.00580.x.